The three studies to be presented and discussed at the meeting include:
Healing of Erosive Esophagitis (EE) and Improvement in Symptoms of Gastroesophageal Reflux Disease (GERD) in 1- and 2-Year-Old Children after Esomeprazole Treatment
Oral Presentation, Tuesday, May 22, 2007, 11:18 AM
150AB, Washington Convention Center
Effect of Esomeprazole on Gastroesophageal Reflux Measured by 24-hour pH- Impedance Monitoring in Preterm Infants and Neonates with Pathological Acid Gastroesophageal Reflux
Poster Presentation, Tuesday, May 22, 8:00 AM
Hall E, Washington Convention Center
Acid-suppressive Effects and Pharmacokinetics After 7 days Repeated Once-daily Dosing of Esomeprazole in Preterm Infants and Neonates with Pathological Acid Gastroesophageal Reflux
Poster Presentation, Tuesday, May 22, 8:00 AM Hall E, Washington Convention Center
About NEXIUM(R) (esomeprazole magnesium)
NEXIUM is approved for the treatment of heartburn and other symptoms associated with GERD, as well as for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8 week course of NEXIUM may be considered. It is indicated to maintain symptom resolution and healing of erosive esophagitis. (Controlled studies do not extend beyond 6 months.) It is indicated for treatment of heartburn and other symptoms associated with GERD.
NEXIUM is approved for the short-term treatment (up to 8 weeks) of GERD in patients aged 12 to 17 years. The safety and effectiveness of NEXIUM for the treatment of symptomatic GERD in patients less than 12 years of ages and for other pediatric uses have not been established.
NEXIUM is als